中文 | EN
Innovative and Efficient R&D systemSystimmuneBaili Pharm/Baili-BioClinical Dynamics

Systimmune Inc. is a clinical-stage bio-pharmaceutical company headquartered in Redmond, WA, that specializes in developing innovative cancer treatments using its well-established drug development platforms. The company's primary focus is on developing bi-specific, multi-specific antibodies, chimeric fusion proteins, and antibody-drug conjugates (ADCs). It has multiple assets from these four classes in various stages of clinical trials for both solid tumor and hematologic indications. In addition to ongoing clinical trials, Systimmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages that represent the cutting edge of biologics development.

Systimmune has a unified set of key technology platforms that enable the advancement of product candidates in all four of its technology chains. It has developed more than ten cutting-edge drug product development lines with its successful operations. The current platforms can produce monoclonal antibodies, bi-specific antibodies, multi-specific antibodies, ADC, and fusion proteins. Furthermore, the company is innovating new technology platforms at the forefront of drug sciences to expand its range of therapeutic modalities. By 2022, the company had applied for approximately 200 patents in 16 different countries or regions across the globe. They have been granted 67 patents for their inventions both domestically and internationally.

Baili Pharmaceutical
Guorui Pharmaceutical
Jingxi Pharmaceutical
Hiatt Technology
Company Address:1#, Building 1,No.161, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City
Sichuan Biokin Pharmaceuticals Co.,Ltd Copyright © 2018 All rights reserved
SICPB No. 17035664-1   
Internet Drug Information Service Qualification Certificate S/N: (C)-FJYX-2022-0343